Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegipanermin (Primary)
Indications Alzheimer's disease
Focus Proof of concept; Therapeutic Use
Acronyms MINDFuL
Sponsors INmune Bio

Most Recent Events

01 Dec 2025 According to an INmune Bio media release, additional MRI analyses from the MINDFuL trial are ongoing and will be presented at subsequent meetings and in publications when available
01 Dec 2025 Results presented in an INmune Bio Media Release.
18 Nov 2025 According to an INmune Bio media release, data from this trial will be presented at 18th Clinical Trials on Alzheimers Disease conference (CTAD), in San Diego, CA on December 1-4, 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com